Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$24.02 USD
+0.94 (4.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $24.04 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
NRIX 24.02 +0.94(4.07%)
Will NRIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NRIX
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Other News for NRIX
TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Oppenheimer Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Nurix Therapeutics price target raised by $2 at Oppenheimer, here's why
Forecasting The Future: 13 Analyst Projections For Nurix Therapeutics
McDonald's downgraded, PayPal upgraded: Wall Street's top analyst calls